Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

In August of 2024, the U.S. Department of Health and Human Services began negotiating drug prices for 10 different types of ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Tiziana’s nasal anti-CD3 therapy has been shown not only to enhance the positive effects of semaglutide, a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and Wegovy when ...

Tiziana’s nasal anti-CD3 therapy has been shown not only to enhance the positive effects of semaglutide, a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and Wegovy when ...

Study: Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study. Image Credit: KK Stock/Shutterstock.com In a recent study published in the ...

As an antagonist, avexitide blocks the GLP-1 receptor. Better known GLP-1 agonists such as Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide activate the receptor. GLP-1 antagonism could ...

Tiziana's nasal anti-CD3 therapy has been shown not only to enhance the positive effects of semaglutide, a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and Wegovy when ...